ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1932

Precapillary Pulmonary Hypertension in Granulomatosis with Polyangiitis: A Case Series with Long-Term Follow-up

Xavier Puéchal1, Xavier Jaïs2, Claire Le Hello3, Anne Grasland4, Assia Eslami1, Jesús Rolando de la Jara Cordero1, Benjamin Terrier1,5, David Launay6, Loïc Guillevin1, Marc Humbert2 and Luc Mouthon for the French Vasculitis Study Group1, 1National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, 2Le Kremlin–Bicêtre University Hospital, Bicêtre, France, 3Caen University Hospital, caen, France, 4Béclère University Hospital, Clamart, France, 5Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, 6Lille University Hospital, Lille, France

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Pulmonary complications and systemic vasculitides

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Vasculitis - Poster II: ANCA-Associated Vasculitis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:  A few isolated case reports of precapillary pulmonary hypertension (PH) in ANCA-associated vasculitides, mostly granulomatosis with polyangiitis (GPA), have been published. The characteristics and outcomes of PH–GPA patients entered in the FVSG database were analyzed.

Methods:  GPA patients with precapillary PH were included from this series. GPA diagnosis was based on ACR classification criteria or the revised Chapel Hill Conference Consensus (CHCC) nomenclature. Patients with connective tissue disease or undergoing hemodialysis were excluded. Chronic thromboembolic pulmonary hypertension required appropriate investigations to be excluded. Precapillary PH was defined as mean pulmonary arterial pressure (mPAP) ≥25 mm Hg at rest, with mean pulmonary capillary wedge pressure (PCWP) ≤15 mm Hg, measured during right heart catheterization (RHC).

Results:  Among the 1065 GPA patients entered in the database, 3 male (0.3%) had precapillary PH; mean age, 43.1 years. All had systemic GPA according to the revised CHCC nomenclature and ACR criteria. Precapillary PH was diagnosed 4 years before GPA in 1 patient and after an average of 1.8 years for the others. All patients had NYHA III dyspnea and confirmed precapillary PH at RHC. In 1 patient, lung biopsy showed histological evidence of granulomatous vasculitis, and arteriolar and venous involvement; a ventilation–perfusion scan detected multiple perfusion defects consistent with thromboembolic disease that was ruled out by pulmonary angiography showing poor peripheral perfusion with a typical “dead tree” aspect, likely due to small-vessel vasculitis. At PH diagnosis, in combination with high-dose glucocorticoids, cyclophosphamide or rituximab was continued in 1 patient each. PH treatment was prescribed only in the patient with preexisting PH who received continuous epoprostenol infusions. Repeat RHC showed significant clinical and hemodynamic improvement in the 3 patients; their mean mPAP decreased from 51.6 (range, 41–70) to 33.0 mm Hg (range, 29–42). The patient with preexisting PH died of sepsis during GPA induction therapy. After treatment, in the patient with multiple ventilation–perfusion-scan defects, no change was observed. With median follow-up post-PH diagnosis of 4.2 years, the 2 other patients are alive, with NYHA class II dyspnea and in complete GPA remission, with median daily prednisone dose at 2.5 mg.

Conclusion:  The data from this first series indicated that GPA can be a rare cause of precapillary PH. Lung small-vessel vasculitis is likely to be causative. GPA-caused precapillary PH may respond to combined high dose glucocorticoids and cyclophosphamide or rituximab.


Disclosure: X. Puéchal, None; X. Jaïs, None; C. Le Hello, None; A. Grasland, None; A. Eslami, None; J. R. de la Jara Cordero, None; B. Terrier, None; D. Launay, None; L. Guillevin, None; M. Humbert, None; L. Mouthon for the French Vasculitis Study Group, None.

To cite this abstract in AMA style:

Puéchal X, Jaïs X, Le Hello C, Grasland A, Eslami A, de la Jara Cordero JR, Terrier B, Launay D, Guillevin L, Humbert M, Mouthon for the French Vasculitis Study Group L. Precapillary Pulmonary Hypertension in Granulomatosis with Polyangiitis: A Case Series with Long-Term Follow-up [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/precapillary-pulmonary-hypertension-in-granulomatosis-with-polyangiitis-a-case-series-with-long-term-follow-up/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/precapillary-pulmonary-hypertension-in-granulomatosis-with-polyangiitis-a-case-series-with-long-term-follow-up/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology